Alpha2-antiplasmin plays a significant role in acute pulmonary embolism.
The importance of pulmonary embolism (PE) due to venous thrombosis is recognized in the treatment of vascular diseases. We have investigated the physiological effects of plasmin generation in experimental acute PE using mice deficient in plasminogen (Plg-/-) or alpha2-antiplasmin (alpha2-AP-/-). PE was induced by continuous induction of venous thrombus in the left jugular vein by endothelial injury due to photochemical reaction. The mortality of wild-type mice was 68.8% at 2 h after the initiation of venous thrombosis and it was significantly reduced in alpha2-AP-/- mice (41.7%). In contrast, Plg-/- mice did not survive. Histological evidence of thromboembolism in the lung was obtained in all mice. However, whereas a strict thromboembolism was observed in Plg-/- mice, only a few thrombi were detected in the lungs of alpha2-AP-/- mice. Plasma fibrinogen levels measured in mice were not different. When alpha2-AP was infused in alpha2-AP-/- mice, the mortality was indistinguishable from wild-type mice. Tissue-type plasminogen activator (tPA) did not reduce the mortality due to acute PE in wild-type mice. However, in alpha2-AP-/- mice, tPA (0.52 mg x kg-1) significantly decreased the mortality compared with that of alpha2-AP-/- mice without tPA. The bleeding time was not significantly prolonged in either type of mice treated with tPA. The lack of plasminogen increases the mortality due to acute PE while a lack of alpha2-AP decreases the mortality rate, which can be further reduced by tPA administration. Therefore, the combination of inhibition of alpha2-AP with thrombolytic therapy could be beneficial in the treatment of acute PE.
Matsuno
H
H
Department of Pharmacology, Gifu University School of Medicine, Tsukasa-machi, Gifu, Japan. leuven@cc.gifu-u.ac.jp
Okada
K
K
Ueshima
S
S
Matsuo
O
O
Kozawa
O
O
D000208:Acute Disease; D000818:Animals; D001760:Bleeding Time; D005340:Fibrinogen / Q000096:biosynthesis / Q000378:metabolism; D007601:Jugular Veins / Q000473:pathology; D008168:Lung / Q000473:pathology; D051379:Mice; D008822:Mice, Transgenic; D011655:Pulmonary Embolism / Q000209:etiology* / Q000378:metabolism; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000096:biosynthesis; D020246:Venous Thrombosis / Q000473:pathology; D000979:alpha-2-Antiplasmin / Q000502:physiology*
D000979:alpha-2-Antiplasmin; D005340:Fibrinogen; D010959:Tissue Plasminogen Activator